tiprankstipranks
Advertisement
Advertisement

JP:4565 Stock Latest News

Nxera trims RSU share issuance after partial forfeiture
Company AnnouncementsNxera trims RSU share issuance after partial forfeiture
2d ago
Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal
PremiumCompany Announcements
Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal
10d ago
Nxera Pharma Returns to Profit on Surging Q1 Revenue, Keeps 2026 Guidance Unchanged
PremiumCompany Announcements
Nxera Pharma Returns to Profit on Surging Q1 Revenue, Keeps 2026 Guidance Unchanged
20d ago
Nxera Pharma Posts Strong Q1 2026 Momentum on Asia-Pacific Deals and Milestones
PremiumCompany Announcements
Nxera Pharma Posts Strong Q1 2026 Momentum on Asia-Pacific Deals and Milestones
20d ago
Nxera Pharma Secures Third AbbVie Milestone in Neurology Collaboration
PremiumCompany Announcements
Nxera Pharma Secures Third AbbVie Milestone in Neurology Collaboration
1M ago
Nxera Pharma Issues New Shares to Fund Japan Employee Stock Plan and Expand RSU Program
PremiumCompany AnnouncementsNxera Pharma Issues New Shares to Fund Japan Employee Stock Plan and Expand RSU Program
1M ago
Nxera Wins Taiwan Approval for QUVIVIQ Insomnia Drug, Eyes 2026 Launch
Premium
Company Announcements
Nxera Wins Taiwan Approval for QUVIVIQ Insomnia Drug, Eyes 2026 Launch
1M ago
Nxera Wins US$22.5m Milestone as Neurocrine Starts Phase 2 Schizophrenia Trial
Premium
Company Announcements
Nxera Wins US$22.5m Milestone as Neurocrine Starts Phase 2 Schizophrenia Trial
1M ago
Nxera Pharma Hits Second Milestone in Lilly Metabolic Disease Partnership
PremiumCompany Announcements
Nxera Pharma Hits Second Milestone in Lilly Metabolic Disease Partnership
1M ago
Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength
PremiumCompany Announcements
Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength
2M ago
Nxera Pharma Refreshes Board While Maintaining Core Leadership Team
PremiumCompany Announcements
Nxera Pharma Refreshes Board While Maintaining Core Leadership Team
2M ago
Nxera Pharma Secures $3 Million Milestone Payment from Centessa
PremiumCompany Announcements
Nxera Pharma Secures $3 Million Milestone Payment from Centessa
3M ago
Nxera Pharma Files for South Korean Approval of Insomnia Drug Daridorexant
PremiumCompany AnnouncementsNxera Pharma Files for South Korean Approval of Insomnia Drug Daridorexant
3M ago
Sosei Group Earnings Call Marks Cautious Transition
Premium
Company Announcements
Sosei Group Earnings Call Marks Cautious Transition
3M ago
Nxera Pharma Revamps Board to Strengthen Governance and Growth Strategy
Premium
Company Announcements
Nxera Pharma Revamps Board to Strengthen Governance and Growth Strategy
3M ago
Nxera Pharma tightens focus as Japan and APAC portfolio powers 2025 growth
PremiumCompany Announcements
Nxera Pharma tightens focus as Japan and APAC portfolio powers 2025 growth
3M ago
Nxera Pharma Slashes Executive Bonuses Following 2025 Results
PremiumCompany Announcements
Nxera Pharma Slashes Executive Bonuses Following 2025 Results
3M ago
Nxera Pharma boosts Japan-APAC portfolio and pipeline as 2025 restructuring sharpens growth focus
PremiumCompany Announcements
Nxera Pharma boosts Japan-APAC portfolio and pipeline as 2025 restructuring sharpens growth focus
3M ago
Nxera Pharma Slashes Executive Bonuses After FY2025 Results to Sharpen Capital Discipline
PremiumCompany Announcements
Nxera Pharma Slashes Executive Bonuses After FY2025 Results to Sharpen Capital Discipline
3M ago
Nxera Pharma Grows Revenue but Widens Loss on R&D and Finance Costs in 2025
PremiumCompany AnnouncementsNxera Pharma Grows Revenue but Widens Loss on R&D and Finance Costs in 2025
3M ago
Nxera Pharma books ¥24.3bn non-cash impairment with no impact on consolidated results
Premium
Company Announcements
Nxera Pharma books ¥24.3bn non-cash impairment with no impact on consolidated results
3M ago
Nxera Pharma Swings to Deeper FY2025 Loss but Guides for Strong Profit Rebound in 2026
Premium
Company Announcements
Nxera Pharma Swings to Deeper FY2025 Loss but Guides for Strong Profit Rebound in 2026
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >